Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
Discontinued
Reference number: GID-TA10609
Following on from information provided to NICE by the company in July 2020 the appraisal of Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.